America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

burger_pills.jpg

Part II.  What Do We Get for All That Money?  A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic;  Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;

Continue reading →

Role of Litigation in Defining Drug Risks_JAMA / BMJ

Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known. Continue reading →

Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM

FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Continue reading →

Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP

Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP Sun, 23 Oct 2005 An investigation by the journal, NATURE (the largest of its kind) reveals that not only do conflicts of interest taint the conduct and . . . Continue reading →

Calls Mounting for FDA Revamp / Americans Are the most medicated population in the world – DHHS

Calls Mounting for FDA Revamp / Americans Are the most medicated population in the world – DHHS Sun, 26 Dec 2004 A government survey by the U.S. Department of Health and Human Services, confirms that Americans are the most medicated population in . . . Continue reading →

NIH: Public Servant or Private Marketer?

NIH: Public Servant or Private Marketer? Wed, 22 Dec 2004 David Willman of the Los Angeles Times provides an important reminder that the FDA is not the only government healthcare agency to have betrayed the public trust and lost its credibility. While . . . Continue reading →